{"id":"NCT03347279","sponsor":"AstraZeneca","briefTitle":"Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma","officialTitle":"A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-23","primaryCompletion":"2020-09-08","completion":"2020-11-12","firstPosted":"2017-11-20","resultsPosted":"2021-11-26","lastUpdate":"2021-11-26"},"enrollment":1061,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"BIOLOGICAL","name":"Experimental: Tezepelumab","otherNames":["Tezepelumab"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tezepelumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma","primaryOutcome":{"measure":"Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma","timeFrame":"From randomisation to Study Week 52.","effectByArm":[{"arm":"Tezepelumab 210mg Q4W","deltaMin":0.93,"sd":null},{"arm":"Placebo","deltaMin":2.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":9},"locations":{"siteCount":289,"countries":["United States","Argentina","Australia","Austria","Brazil","Canada","France","Germany","Israel","Japan","Russia","Saudi Arabia","South Africa","South Korea","Taiwan","Ukraine","United Kingdom","Vietnam"]},"refs":{"pmids":["40782846","40285963","39514041","39326921","38802635","37772607","37723356","37619779","37263380","37015033","36702146","36253275","33979488","33050934"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00007&amp;attachmentIdentifier=103f6433-96f8-44c4-b837-d7315e83136d&amp;fileName=d5180c00007-csp-v5-14.May.2020_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00007&amp;attachmentIdentifier=3d32e500-6365-408d-bdb5-c145f83f1d2b&amp;fileName=d5180c00007-sap-ed-4_22.Oct.2020_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":528},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Sinusitis","Bronchitis"]}}